ArticleCommunications biology2026
Deep learning-based in silico labeling for analyzing morphological features of MSCs to predict immunomodulatory capacity.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deep learning-based in silico labeling for analyzing morphological features of MSCs to predict immunomodulatory capacity.Communications biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular morphology, a critical manifestation of biological characteristics, is linked to functions. In traditional cell detection, invasive labeling and detection methods not only compromise cellular viability but also entail labor-intensive workflows. Here we presented a non-invasive artificial intelligence framework that integrated deep learning (DL) and machine learning (ML) to predict the immunomodulatory capacity of mesenchymal stem cells (MSCs) through morphological profiling. The improved PreAct-ResNet50 encoder-decoder architecture was used to achieve high-accuracy instance segmentation of cells and nuclei, enabling quantification of morphological features. A LightGBM-based predictive model was subsequently employed to predict MSCs immunomodulatory biomarkers through morphological features. This dual-model system demonstrated satisfactory cell segmentation and biological characteristics prediction capabilities through performance testing. Our method provided an efficient, non- invasive tool for real-time MSCs potency assessment, which could enhance quality controls in cell therapy manufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.